interferon-beta 1b + ribavirin

This is a combination therapy consisting of interferon-beta 1b and ribavirin. Interferon-beta 1b is a recombinant cytokine that modulates the immune response, primarily by enhancing antiviral defenses through upregulation of interferon-stimulated genes and inhibition of viral replication. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity, inhibiting viral RNA synthesis and mRNA capping. The combination has been investigated as part of multi-drug regimens for the treatment of viral infections such as COVID-19, aiming to leverage both direct antiviral effects (ribavirin) and immunomodulatory/antiviral signaling (interferon-beta 1b). Clinical studies have evaluated this combination—often alongside other antivirals—for its potential to reduce viral load and improve clinical outcomes in hospitalized patients with mild to moderate COVID-19[1][2][3][4][5].